SOAT1 and cancer: Notwithstanding the large number of existing data linking these drugs to impaired T cell responses (186), results obtained from these recent clinical studies might provide valuable insights into the therapeutic potential of JAK/STAT inhibitors and their combination strategies in improving outcomes for cancer patients.